Acton, Massachusetts-based Insulet launched Omnipod 5 for individuals aged two years and older with type 1 diabetes.
The latest-generation Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January 2022. Insulet commenced its U.S. full-market launch in August 2022. The Omnipod 5 picked up CE mark approval for ages two and up in September of last year.
Omnipod 5, a tubeless pod, features SmartAdjust technology. It integrates with the Dexcom 6 continuous glucose monitor (CGM). With CGM data, SmartAdjust predicts where glucose will be 60 minutes into the future every five minutes. Omnipod 5 then increases, decreases, or pauses insulin delivery based on the user’s desired and customized glucose target.
The device also features the Omnipod 5 mobile app with an integrated SmartBolus calculator, too. Users can download the app onto a compatible smartphone or use the Omnipod 5 controller.
“Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes,” said Jim Hollingshead, Insulet president and CEO. “Every day, we hear how this revolutionary experience of Omnipod 5 reduces the burden and improves quality of life for people with diabetes, and we are excited to make a difference in other parts of the world, beginning with the UK. We are committed to making Omnipod 5 an option for as many people as possible, as quickly as we can, and working hard to secure broad access globally.”
More on the Insulet Omnipod 5 launch in the UK and beyond
Insulet said it is working in partnership with the UK’s National Health Service (NHS) “at all levels.” They aim to ensure access to Omnipod 5 for people with type 1 diabetes.
The National Institute for Health and Care Excellence (NICE) is also expected to grant approval to hybrid closed-loop insulin delivery systems in the UK and Wales in the near future. Insulet also expects to release Omnipod 5 in Germany this coming fall.
“With NICE set to approve hybrid closed loop in England and Wales later this year, we are delighted that more hybrid closed loop systems such as Omnipod 5 are becoming available to help people manage their type 1 diabetes,” said Karen Addington, CEO at JDRF UK. “Diabetes management is very personal, so access to a range of technology options is crucial. A wider choice of hybrid closed loop systems offers people with type 1 diabetes evidence-based treatment they can trust to support them to manage their condition with confidence.”
